Literature DB >> 19775901

Impact of neo-adjuvant radiochemotherapy on bronchial tissue viability.

Martina Hampel1, Iris Dally, Thorsten Walles, Volker Steger, Stefanie Veit, Thomas Kyriss, Godehard Friedel.   

Abstract

OBJECTIVE: In the treatment of advanced stages of lung cancer, increasingly more multimodality approaches applying radiotherapy and/or chemotherapy in a neo-adjuvant setting are being introduced. The impact of induction therapy, especially radiotherapy, on bronchial tissue viability has not been investigated so far.
METHODS: In 2008, we determined the tissue viability of bronchial segments obtained during surgery in 45 consecutive patients, including patients after neo-adjuvant radiochemotherapy (RCTX). Bronchial tissue viability was analysed by histology, life-dead assay and cell proliferation in tissue-specific culture media. Biomedical findings were compared with the clinical course of the patients.
RESULTS: Tissue samples of 44 patients were included into this study. Fourteen patients (32%) had undergone neo-adjuvant RCTX. Histology and life-dead assay of the bronchial segments did not show significant differences. While patient age, sex, tumour entity and site of resection had no influence on cell proliferation in vitro, previous RCTX resulted in a 46% decrease of bronchial tissue viability (P=0.01). However, this effect was not reflected by the clinical course of the operated patients.
CONCLUSIONS: Neo-adjuvant RCTX reduces bronchial tissue viability substantially. However, this impairment does not necessarily translate into an increased rate of postoperative bronchial insufficiencies. Standard histological work-up is not sensitive enough to characterise changes in bronchial tissue viability following RCTX. Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19775901     DOI: 10.1016/j.ejcts.2009.08.021

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  1 in total

1.  Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib.

Authors:  Ichiro Sakanoue; Hiroshi Hamakawa; Reiko Kaji; Yukihiro Imai; Nobuyuki Katakami; Yutaka Takahashi
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.